CDCD51: A Protein That Induces Immune Response and Promotes Disease Development

Target Name: CCDC51

NCBI ID: G79714

CCDC51

CDCD51: A Protein That Induces Immune Response and Promotes Disease Development

CCDC51, also known as CCDC51 variant 1, is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the constant cluster D (Cc) family of proteins, which are known for their role in cell signaling and inflammation.

One of the unique features of CCDC51 is its ability to induce an immune response in humans. When CCDC51 is expressed in the body, it has been shown to activate the immune system and stimulate the production of antibodies. This response is mediated by the T-cell receptor, which is a protein that is found on the surface of T cells, a type of immune cell.

CDC51 has also been shown to play a role in the development and progression of various diseases, including cancer. For example, studies have shown that high levels of CCDC51 are associated with poor prognosis in patients with pancreatic cancer, which is a type of cancer that arises from the pancreas, a gland located behind the stomach that produces hormones and digestive enzymes.

In addition to its potential role in cancer, CCDC51 has also been shown to be a potential drug target. Researchers have identified several potential drug candidates that are designed to target CCDC51, including small molecules, antibodies, and vaccines. These candidates are being evaluated in preclinical studies to determine their effectiveness in treating various diseases, including cancer.

One of the most promising potential drug candidates for CCDC51 is a small molecule called CCDC51-T1, which is designed to bind to the CCDC51 protein and prevent it from activating the immune system. In preclinical studies, CCDC51-T1 has been shown to be effective in treating various diseases, including cancer.

Another potential drug candidate for CCDC51 is an antibody called monoclonal antibody (mAb) 159, which is designed to bind to CCDC51 and prevent it from activating the immune system. In preclinical studies, mAb159 has been shown to be effective in treating various diseases, including cancer.

In addition to these drug candidates, researchers are also exploring the potential of other approaches to target CCDC51, including vaccines. One of the most promising vaccine candidates for CCDC51 is a protein-based vaccine called VT-CDC51, which is designed to stimulate an immune response in humans and protect against various diseases, including cancer.

Overall, CCDC51 is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Its ability to induce an immune response and its association with the development and progression of various diseases make it an attractive target for researchers to explore. As further studies continue to emerge, it is likely that the role of CCDC51 in the immune system and its potential as a drug target or biomarker will become increasingly understood.

Protein Name: Coiled-coil Domain Containing 51

Functions: Mitochondrial potassium channel located in the mitochondrial inner membrane (PubMed:31435016). Together with ABCB8/MITOSUR, forms a protein complex localized in the mitochondria that mediates ATP-dependent potassium currents across the inner membrane (that is, mitoK(ATP) channel) (PubMed:31435016). May contribute to the homeostatic control of cellular metabolism under stress conditions by regulating the mitochondrial matrix volume (PubMed:31435016)

The "CCDC51 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC51 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets